To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 4

Conditions: AIDS

Treatments: Behavioral: Compliance

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT00207168

The TEddI Study

AI454-194

Details and patient eligibility

About

To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 or older, required lab results, currently taking no more than two of the proposed once daily arm medications with medications administered twice daily and women of child bearing potential.

Exclusion criteria

• virological failure, serious medical condition, known toxicities to any of the once daily arm medications, lab abnormalities, women who are pregnant/breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)